Bristol Myers Squibb and Cambridge-based bluebird bio have announced FDA approval for Abecma, a personalized immune cell therapy for the treatment of certain patients with multiple myeloma. As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of […]

Phase 2 results presented today by Eli Lilly expand on previously reported top-line data that found donanemab met its primary endpoint and showed significant slowing of decline on a composite measure of cognition and daily function in patients with early symptomatic Alzheimer’s disease compared to placebo. Additionally, data from secondary analyses showed donanemab consistently slowed cognitive […]

Thermo Fisher has announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new […]

The Massachusetts Biotechnology Council’s newly-released 2020 Massachusetts Biopharma Funding Report shows that the Massachusetts biopharma industry experienced its best funding year on record. In 2020, venture capital investment in Massachusetts-based companies reached $5.8 billion, surpassing 2018’s previous record high of $4.8 billion. In addition, 21 Massachusetts-based biopharma companies went public in 2020, a 110% increase […]

The FDA has approved Sarepta Therapeutics Amondys 45, an antisense oligonucleotide, for the treatment of Duchenne muscular dystrophy (DMD) in certain patients. Consistent with the accelerated approval pathway, the continued approval of Amondys 45 may be contingent on confirmation of a clinical benefit in confirmatory trials. The Essence trial – a placebo-controlled confirmatory trial to […]